tbuckley/cabot-search huggingface dataset:
PWE-155 Should Patients with Human Immunodeficiency Virus and Gastrointestinal Symptoms be Routinely Tested for Pancreatic Exocrine Insufficiency?
Authors: JA Campbell, DS Sanders, AD Hopper
Journal: Gut (2016)

<h3>Introduction</h3> Diarrhoea and gastrointestinal (GI) symptoms are common symptom in patients with human immunodeficiency virus (HIV). Malabsorption secondary to pancreatic exocrine insufficiency (PEI) has been reported in patients with HIV. Treatment with pancreatic enzyme replacement therapy (PERT) improves symptoms and reduces complications of PEI (malnutrition and osteoporosis). We aimed to calculate the prevalence of PEI in patients with HIV referred to gastroenterology secondary care clinics for persistent GI symptoms. <h3>Methods</h3> All patients tested for PEI between 2010 and 2014 were identified. Presenting symptoms and presence of HIV were noted. Faecal elastase (FEL-1) was used to assess pancreatic function with FEL-1 &lt;200μg/g defined as abnormal. Co-morbidities, response to PERT and abdominal imaging results were noted. Prevalence of PEI was compared in patients with and without HIV. Patients treated with PERT were identified on follow up and a positive symptom response noted. <h3>Results</h3> 84 patents were identified during the period. 21 were identified with HIV (mean age 47.5, SD 9.8, 85.7% male). 12/21 (57.1%) HIV patients with GI symptoms had low FEL-1 compared to 8/63 (12.7%) patients with GI symptoms without HIV (p =&lt; 0.0001). The most common presenting GI symptom in patients tested for FEL-1 was diarrhoea, (85.7% in both groups) other symptoms included abdominal pain (HIV 9.5%, non HIV 19.0%), weight loss (HIV 0%, control 9.5%) and bloating (HIV 4.8%, control 6.3%). 10/12 (83.3%) HIV patients with low FEL-1 had abdominal imaging. Pancreatic abnormalities were detected in 2/10 cases (20%). 7/8 (87.5%) controls with low FEL-1 had imaging, 3/7 (42.9%) had pancreatic abnormalities. In both groups pancreatic calcification and atrophy were detected. No malignancy was identified. 9/12 (72.5%) HIV patients and 5/8 (62.5%) controls were treated with PERT. 9/9 (100%) HIV patients reported symptomatic improvement; 4/5 (80%) controls derived benefit. Doses prescribed varied from 60,000–140,000 units/day across both groups. <h3>Conclusion</h3> Given its significantly high yield and response to treatment FEL-1 should be performed to check for PEI in patients with HIV presenting with gastrointestinal symptoms or weight loss. <h3>Disclosure of Interest</h3> None Declared
Treatment with Granulocyte Colony-Stimulating Factor after Allogeneic Transplantation Increases the Risk of Hepatic Veno-Occlusive Disease and Death: A Retrospective Analysis of 440 Cases at a Single Center.
Authors: Miwa Sakai, Kazuteru Ohashi, Takeshi Kobayashi, Takuya Yamashita, Hideki Akiyama, Hisashi Sakamaki
Journal: Blood (2005)
PO05IS RADIOTHERAPY EFFECTIVE IN THE MANAGEMENT OF PITUITARY TUMOURS? THE NHS TAYSIDE EXPERIENCE
Authors: Hannah Lord, Malinder Singh
Journal: Neuro-Oncology (2015)

INTRODUCTION: Radiotherapy is a potential treatment of pituitary adenoma, after incomplete excision or when hormone secretion remains problematic. We audited outcomes of patients in NHS Tayside who have received radiotherapy for pituitary tumours. METHOD: Patients between 2000 and 2014 were identified using the departmental database. Patient notes and computer records reviewed. Type of pituitary adenoma, dose of radiotherapy, dates of treatment, tumour re-growth, control of hormone production, and complications were recorded. RESULTS: 38 patients identified, 3 excluded due to lack of data. 35 assessed, with 10 non-functioning and 25 functioning tumours. Of the functioning tumours, 7 growth hormone (GH); 7 adrenocorticotrophic hormone (ACTH); 7 follicular stimulating hormone (FSH); 4 prolactin (PL) and 1 leutenising hormone (LH). Of these, one was mixed producing both PL and GH. All patients with functioning-pituitary tumours had hormone secretion brought under improved control. Median follow-up 80 months. 9/10 (90%) patients with non-functioning adenomas had no evidence of tumour recurrence on serial MRI. One patient had tumour recurrence and died at second surgery. Median follow-up 78.5 months. No long term complications identified. CONCLUSION: Radiation therapy is an effective adjunct in managing both functioning and non-functioning pituitary tumours, with 100% and 90% control rates respectively. Long term neuro-imaging and endocrinological assessments are essential, as delayed complications can arise after treatment, but our practice of 45Gy in 25 fractions appears to be safe with no long-term negative sequelae.
Seasonal Variation in Man. (A Theory.)
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L
Authors: Fabrizia Favale, Kahia Messaoudi, Leila N. Varghese, Siham Boukour, Christian Pecquet, Vitalina Gryshkova, Jean Philippe Defour, Roxana-Irina Albu, Olivier Bluteau, Paola Ballerini, Guy Leverger, Isabelle Plo, Najet Debili, Hana Raslova, Remi Favier, Stefan N. Constantinescu, William Vainchenker
Journal: Blood (2016)
NK Cell Recognition of Hepatocellular Carcinoma by Specific Induction of NKG2D Ligands Following Treatment with the Histone Deacetylase Inhibitor Sodium Valproate.
Authors: Helmut R. Salih, Sorin Armeanu, Ulrich M. Lauer, Sascha Venturelli, Anita Pathil, Irina Smirnow, Annika Wagner, Lothar Kanz, Alexander L. Steinle, Michael Bitzer
Journal: Blood (2004)
The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1).
Authors: Torsten Haferlach, Katja Macijewski, Tamara Weiss, Ulrike Bacher, Susanne Schnittger, Wolfgang Kern, Alexander Kohlmann, Hans-Ulrich Klein, Marco Vignetti, Alfonso Piciocchi, Paola Fazi, Maria Paola Martelli, Stefano Aldo Pileri, Miriam Miesner, Antonella Santucci, Teresa Marafioti, Claudia Haferlach, Franco Mandelli, Brunangelo Falini
Journal: Blood (2009)
Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children’s Oncology Group
Authors: George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Roland B. Walter
Journal: Blood (2014)
Biomaterials and Culture Technologies for Regenerative Therapy of Liver Tissue
Authors: Roman A. Perez, Cho‐Rok Jung, Hae‐Won Kim
Journal: Advanced Healthcare Materials (2016)

Regenerative approach has emerged to substitute the current extracorporeal technologies for the treatment of diseased and damaged liver tissue. This is based on the use of biomaterials that modulate the responses of hepatic cells through the unique matrix properties tuned to recapitulate regenerative functions. Cells in liver preserve their phenotype or differentiate through the interactions with extracellular matrix molecules. Therefore, the intrinsic properties of the engineered biomaterials, such as stiffness and surface topography, need to be tailored to induce appropriate cellular functions. The matrix physical stimuli can be combined with biochemical cues, such as immobilized functional groups or the delivered actions of signaling molecules. Furthermore, the external modulation of cells, through cocultures with nonparenchymal cells (e.g., endothelial cells) that can signal bioactive molecules, is another promising avenue to regenerate liver tissue. This review disseminates the recent approaches of regenerating liver tissue, with a focus on the development of biomaterials and the related culture technologies.
Deletion 13 by FISH Provides Prognostic Information on Overall Survival and Time to Progression Independent of Serum Beta 2 Microglobulin and Bone Marrow Plasma Cell Labeling Index in Myeloma Patients Undergoing Stem Cell Transplantation.
Authors: Morie Abraham Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kim J. Henderson, Scott VanWier, Greg Ahmann, Rafael Fonseca
Journal: Blood (2004)
PTU-109 Immunosuppression; An Independant Risk Factor in Catheter Related Blood Stream Infections in Patients On Long Term Parenteral Nutrition?: Abstract PTU-109 Table 1
Authors: S Oke, D Ismail, SM Gabe
Journal: Gut (2016)

<h3>Introduction</h3> Catheter related blood stream infections (CRBSI) are a serious complication for patients on home parenteral nutrition (HPN).<sup>1</sup> 20% of patients on HPN at our institute take immunosuppressive medication. Little data is available to assess if immunosuppression confers any increased risk of CRBSI. We have therefore performed a retrospective cohort study on patients on HPN, cared for at St Mark’s Hospital (Harrow) to assess if immunosuppression increases susceptibility to CRBSI. <h3>Methods</h3> The Intestinal Failure Unit Database (a local database of all HPN patients) was interrogated between 01/01/2013 to 1/10/2015. Patients on HPN were divided into two arms; those with confirmed CRBSI and those without. The two groups were sub catagorised into immunosuppressed and non-immunosuppressed, and then catagorised by immunosuppression type and disease type. <h3>Results</h3> A total of 149 patients (227 separate episodes) (age 18–86) with CRBSI &amp; 170 patients (age 16–85) without CRBSI were identified. The distribution of disease types was broadly similar for both groups of patients with 39 (26%) patients with IBD, 26 (17%) with mesenteric ischaemia, 30 (20%) with motility disorders &amp; 32 (21%) with surgical complications in the CRBSI group. This compared to 44 (26%) with IBD, 23 (14%) with mesenteric ischaemia, and 14 (8%) with motility disorder &amp; 37 (22%) with surgical complications in the non CRBSI group. 25 (17%) of the CRBSI group were immunosuppressed while 39 (23%) in the non CRBSI group were immunosuppressed. For each disease subtype CRBSI was compared against immunosuppression status (Fisher’s exact test). It was found that there was no statistical increase in risk in CRBSI with immunosuppression p = 0.07 (&gt;0.05) (see table 1) No significant differences were seen according to the type of immunosuppression used (p = 0.6), or if patients were on dual or single immunosuppression (p = 1.0). <h3>Conclusion</h3> Although there is a clinical assumption that immunosuppression is a risk factor for developing CRBSI, our large retrospective cohort study has shown that this does not appear to be an independent risk factor in the development in patients on HPN. <h3>Reference</h3> 1 Buchman AL, Moukarzel A, Goodson B, Herzog F, Pollack P, Reyen L, Alvarez M, Ament ME, Gornbein J. Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. <i>JPEN J Parenter Enteral Nutr</i> 1994;<b>18</b>(4):297–302. <h3>Disclosure of Interest</h3> None Declared
SP0179 Transition Care Programmes: A North American Perspective
Authors: L. Tucker
Journal: Annals of the Rheumatic Diseases (2016)

Adolescents with rheumatic diseases frequently continue to require rheumatologic care into adulthood, either due to continued active disease and requirement for treatment, or management of sequelae of disease. In addition, these vulnerable adolescents need to manage transition in schooling, work, living situation, health insurance coverage, and peer relationships. In the recent years, there has been increased focus on improving transition support to adolescents with chronic diseases, resulting in a variety of specialized programs and resources. Objectives for this talk are: a) To describe North American transition guidelines and models for youth with rheumatic diseases, and how these are applied across different centres and regions. b) To compare transition practices in pediatric rheumatic programs in North America. c) To review new transition planning resources for use in the pediatric rheumatology setting. <h3>Disclosure of Interest</h3> None declared
The Platelet Glycoprotein Ib-von Willebrand Factor Interaction Activates the Collagen Receptor α2β1 and the Two Adhesive Receptors then Collaborate to Fully Activate Platelets to Form Thrombi.
Authors: Junmei Chen, Jody L. Whitelock, Lisa D. Morales, Jose A. Lopez, Miguel A. Cruz
Journal: Blood (2004)
Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.
Authors: Hagop M. Kantarjian, Elias Jabbour, Francis J. Giles, Kapil N. Bhalla, Javier Pinilla-Ibarz, Richard A. Larson, Norbert Gattermann, Oliver G. Ottmann, Jim Wang, Richard C. Woodman, Michele Baccarani, Philipp D. le Coutre, Jorge Cortes
Journal: Blood (2009)
Abstract 4878: The Association of Osteopontin with Cardiac Fibrosis and the Responsiveness to Beta-Blockers in Patients with Heart Failure
Authors: Hiroshi Okamoto, Shinpei Nonen, Yasushi Fujio, Yutaka Matsui, Yasuhiko Takemoto, Minoru Yoshiyama, Junichi Yoshikawa, Akira Kitabatake, Junichi Azuma
Journal: Circulation (2008)
Prognostic Impact of Cancer Testis Antigens Expression in Advanced Stage Multiple Myeloma Patients.
Authors: Valéria C.C. Andrade, André L. Vettore, Manuella S.S. Almeida, José S.R. Oliveira, Maria de Lourdes L.F. Chauffaille, Mihoko Yamamoto, Adagmar Andriolo, Roberta S. Felix, Fabrício Carvalho, Otávia L. Caballero, Amélia G. Araujo, Rodrigo A. Panepucci, Marco A. Zago, Gisele W.B. Colleoni
Journal: Blood (2007)
Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)
Authors: Ellen K. Ritchie, Danielle C. Marshall, Molly D. Greenberg, Tania J. Curcio, Ashley E. Giambrone, Paul Christos, Eric J. Feldman, Joseph M. Scandura, Gail J. Roboz
Journal: Blood (2014)
Safety and Efficacy of Iron Chelation with Deferasirox in Adult Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Young-Woo Jeon, Byung-Sik Cho, Hee-Je Kim, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Ki-Seong Eom, YooJin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min
Journal: Blood (2015)
T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies
Authors: Lorenz Jahn, Renate S. Hagedoorn, Pleun Hombrink, Michel G.D. Kester, Dirk M. van der Steen, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Journal: Blood (2015)
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway
Authors: Y Shen, C S Park, K Suppipat, T-A Mistretta, M Puppi, T M Horton, K Rabin, N S Gray, J P P Meijerink, H D Lacorazza
Journal: Leukemia (2016)
Healthy Behaviors Potentially Due to Calorie Restriction—Reply
Authors: Corby K. Martin, Manju Bhapkar, Susan B. Roberts
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Role of ABL Gene Mutations in Chronic Myeloid Leukemia Patients Resistant to Imatinib and Results of Treatment Shift to Second-Generation Tyrosine Kinase Inhibitors
Authors: Silvia Marce, Lurdes Zamora, Marta Cabezon, Blanca Xicoy, Concha Boqué, Diana Dominguez, Jordi Ribera, Cristalina Fernandez, Lluis Rodriguez, Imma Portal, Esther Plensa, Patricia Velez, Jorge Medina, Javier Grau, Marisol Xandri, Jose-Tomas Navarro, Alberto Fernandez de Sevilla, Josep-Maria Ribera, Evarist Feliu, Fuensanta Millá
Journal: Blood (2011)
Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial
Authors: Mitesh Patel, Kiran Agarwal, Qadeer Arshad, Mohamed Hariri, Peter Rea, Barry M Seemungal, John F Golding, Jonny P Harcourt, Adolfo M Bronstein
Journal: The Lancet (2016)

Ménière's disease is characterised by severe vertigo attacks and hearing loss. Intratympanic gentamicin, the standard treatment for refractory Ménière's disease, reduces vertigo, but damages vestibular function and can worsen hearing. We aimed to assess whether intratympanic administration of the corticosteroid methylprednisolone reduces vertigo compared with gentamicin.In this double-blind comparative effectiveness trial, patients aged 18-70 years with refractory unilateral Ménière's disease were enrolled at Charing Cross Hospital (London, UK) and Leicester Royal Infirmary (Leicester, UK). Patients were randomly assigned (1:1) by a block design to two intratympanic methylprednisolone (62·5 mg/mL) or gentamicin (40 mg/mL) injections given 2 weeks apart, and were followed up for 2 years. All investigators and patients were masked to treatment allocation. The primary outcome was vertigo frequency over the final 6 months (18-24 months after injection) compared with the 6 months before the first injection. Analyses were done in the intention-to-treat population, and then per protocol. This trial is registered with ClinicalTrials.gov, number NCT00802529.Between June 19, 2009, and April 15, 2013, 256 patients with Ménière's disease were screened, 60 of whom were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone. In the intention-to-treat analysis (ie, all 60 patients), the mean number of vertigo attacks in the final 6 months compared with the 6 months before the first injection (primary outcome) decreased from 19·9 (SD 16·7) to 2·5 (5·8) in the gentamicin group (87% reduction) and from 16·4 (12·5) to 1·6 (3·4) in the methylprednisolone group (90% reduction; mean difference -0·9, 95% CI -3·4 to 1·6). Patients whose vertigo did not improve after injection (ie, non-responders) after being assessed by an unmasked clinician were eligible for additional injections given by a masked clinician (eight patients in the gentamicin group vs 15 in the methylprednisolone group). Two non-responders switched from methylprednisolone to gentamicin. Both drugs were well tolerated with no safety concerns. Six patients reported one adverse event each: three in the gentamicin group and three in the methylprednisolone group. The most common adverse event was minor ear infections, which was experienced by one patient in the gentamicin group and two in the methylprednisolone group.Methylprednisolone injections are a non-ablative, effective treatment for refractory Ménière's disease. The choice between methylprednisolone and gentamicin should be made based on clinical knowledge and patient circumstances.Ménière's Society and National Institute for Health Research Imperial Biomedical Research Centre.
In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease
Authors: Shaneice Mitchell, Shelley Orwick, Matthew Cannon, Virginia M. Goettl, Taylor D. LaFollette, Erkan Baloglu, William Senapedis, Alison R. Walker, Bhavana Bhatnagar, Alice S. Mims, Rebecca B. Klisovic, Sumithira Vasu, William Blum, David M. Lucas, James S. Blachly, Ramiro Garzon, Clara D. Bloomfield, Rosa Lapalombella, John C. Byrd
Journal: Blood (2015)
Low Incidence of Post-Transplant EBV-Related Disease After Alemtuzumab-Mediated T Cell Depletion Is Explained by the Differential Susceptibility to Alemtuzumab of B Cells and Protective CD8 and CD4 T Cells
Authors: Constantijn J.M. Halkes, Inge Jedema, Judith Olde Wolbers, Esther M van Egmond, Peter A. Von Dem Borne, Erik W.A.F. Marijt, J.H.Frederik Falkenburg
Journal: Blood (2010)
Allogeneic SCT in Multiple Myeloma: Limited Predictive Value of Chimerism Analysis for Heralding Relapse/Progression Due to Extramedullary Disease
Authors: Leo Rasche, Christoph Röllig, Stephan Mielke, Goetz Ulrich Grigoleit, Martin Schreder, Sophia Danhof, Martin Bornhäuser, Hermann Einsele, Christian Thiede, Stefan Knop
Journal: Blood (2015)